Tier 4 — mechanistic

Senolytic Agent Improve the Benefit of Platelet-Rich Plasma and Losartan

Steadman Philippon Research Institute study team
ClinicalTrials.gov trial registry record 2021

Bibliography

Trial registry
View on ClinicalTrials.gov Registered trial — results not yet published in a peer-reviewed journal.
Funding
Sponsor: Steadman Philippon Research Institute.
Competing interests
Not reported in the registry record.

Study snapshot

DesignPhase 1/2 randomized trial testing perioperative fisetin in the context of PRP and losartan.
ModelAdults undergoing treatment for femoroacetabular impingement or labral tear.
SamplePlanned enrollment: 68 participants.
InterventionFisetin approximately 20 mg/kg/day on two days before surgery and repeated on paired days around months 1, 2 and 3 after surgery, alongside PRP and/or losartan depending on study arm.
DurationRepeated perioperative and postoperative courses with clinical follow-up.
EndpointsSafety; Hip function and patient-reported outcomes; Senescence/SASP biomarkers; PRP/losartan-related outcomes

What the study showed, in plain terms

This orthopedic trial tests fisetin around hip surgery in combination with other interventions including platelet-rich plasma and losartan. It is not a clean fisetin-monotherapy study.

The September 2026 review lists recruitment status as unknown, with no results available. Until arm-specific data are reported, no clinical benefit can be assigned to fisetin.

Key findings

  • Planned enrollment is 68.
  • Fisetin is delivered in repeated two-day perioperative/postoperative courses.
  • The intervention context includes PRP and losartan.

What this study can and cannot tell us

  • No posted results.
  • Multiple concurrent interventions complicate attribution.
  • Registry status is outdated/unknown.

Editorial review

Reviewed by the Biohack Blueprint research team

Last verified

Dr. Khaled Mahmoud, MBBChCritical Care Medicine, Longevity Science & Editorial Direction Dr. Amr Yasser, PhDCardiometabolic, Musculoskeletal, Gut & Bioavailability Dr. Abdulla Mostafa, PhDCellular Senescence, Neurological, Mitochondrial & Brain-Ageing Biology